Home » Stocks » Springworks Therapeutics

Springworks Therapeutics, Inc. (SWTX)

Stock Price: $37.40 USD 1.26 (3.49%)
Updated Jul 14, 2020 12:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.61B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 43.00M
EPS (ttm) -13.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $37.40
Previous Close $36.14
Change ($) 1.26
Change (%) 3.49%
Day's Open 36.25
Day's Range 35.28 - 37.67
Day's Volume 95,540
52-Week Range 17.02 - 49.79

More Stats

Market Cap 1.61B
Enterprise Value 1.30B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 43.00M
Float 15.70M
EPS (basic) n/a
EPS (diluted) -13.84
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.65M
Short Ratio 7.13
Short % of Float 22.45%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.32
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 311.64M
Net Cash / Share 7.25
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -15.55%
ROE -35.37%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(39.57% upside)
Current: 37.40
Target: 52.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-59.24-18.49
Net Income-58.31-17.81
Shares Outstanding43.01341
Earnings Per Share-3.81-
Operating Cash Flow-47.44-14.17
Capital Expenditures-0.67-0.29
Free Cash Flow-48.11-14.46
Cash & Equivalents32846.19
Net Cash / Debt32846.19
Book Value322-19.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Springworks Therapeutics, Inc.
Country United States
Employees 60
CEO Saqib Islam

Stock Information

Ticker Symbol SWTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SWTX
IPO Date June 5, 1987


SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.